The use of lithium appears to be in decline, The use of lithium appears to be in decline, possibly because of insufficient training of possibly because of insufficient training of psychiatrists in the use of lithium therapy psychiatrists in the use of lithium therapy and the aggressive marketing of alternative and the aggressive marketing of alternative medications that are patentable and theremedications that are patentable and therefore more profitable (Fieve, 1999 ; Jefferson, fore more profitable (Fieve, 1999; Jefferson, 2005) . A decline in lithium use has been 2005). A decline in lithium use has been demonstrated by empirical studies in the demonstrated by empirical studies in the USA (Fenn USA (Fenn et al et al, 1996; Blanco , 1996; Blanco et al et al, , 2002) , Canada (Shulman 2002) , Canada (Shulman et al et al, 2003), and , 2003) , and Germany, Switzerland and Austria Germany, Switzerland and Austria (Wolfsperger (Wolfsperger et al et al, 2007) . In a study of , 2007) . In a study of prescription patterns for Americans with prescription patterns for Americans with bipolar disorder in 2002 -3, Baldessarini bipolar disorder in 2002 -3, Baldessarini et et al al (2007 found that lithium was prescribed (2007) found that lithium was prescribed for only 7.5% of patients initially but was for only 7.5% of patients initially but was retained in monotherapy for much longer retained in monotherapy for much longer than other treatments, which were augmenthan other treatments, which were augmented or discontinued. The decline in lithium ted or discontinued. The decline in lithium use is not universal; lithium use has use is not universal; lithium use has increased in Spain (Castells increased in Spain (Castells et al et al, 2006) , 2006) and remains high in England, where a and remains high in England, where a recent study found that approximately half recent study found that approximately half of patients with bipolar disorder are of patients with bipolar disorder are prescribed lithium (Anderson prescribed lithium . 2004).
PROPHYLAXIS PROPHYLAXIS
The decline in lithium use has occurred as The decline in lithium use has occurred as the evidence base supporting its use has the evidence base supporting its use has strengthened. Although the efficacy of strengthened. Although the efficacy of lithium in treating acute mania is longlithium in treating acute mania is longestablished, doubts remained about its established, doubts remained about its This meta-analysis of 14 randomised This meta-analysis of 14 randomised controlled trials, of which 8 included placebo controlled trials, of which 8 included placebo arms, provides strong evidence for the arms, provides strong evidence for the prophylactic efficacy of lithium, which prophylactic efficacy of lithium, which prevented relapse to any mood episode with prevented relapse to any mood episode with a hazard ratio of 0.68 (95% CI 0.53-0.86; a hazard ratio of 0.68 (95% CI 0.53-0.86; Smith Smith et al et al, 2007) . The overall prophylactic , 2007). The overall prophylactic efficacy of lithium was largely explained by efficacy of lithium was largely explained by the reduction in manic relapses (hazard the reduction in manic relapses (hazard ratio 0.53, 95% CI 0.35-0.79). Lithiumratio 0.53, 95% CI 0.35-0.79). Lithiumtreated patients also had fewer depressive treated patients also had fewer depressive relapses, but this effect was smaller and relapses, but this effect was smaller and not statistically significant. not statistically significant.
The efficacy of lithium in bipolar disThe efficacy of lithium in bipolar disorder is recognised by the most recent order is recognised by the most recent evidence-based clinical guidelines for bievidence-based clinical guidelines for bipolar disorder, which recommend it as a polar disorder, which recommend it as a first-line treatment ( 
SUICIDAL BEHAVIOUR SUICIDAL BEHAVIOUR
In two recent meta-analyses lithium has In two recent meta-analyses lithium has also been shown to reduce the incidence also been shown to reduce the incidence of suicide and suicidality in people with of suicide and suicidality in people with mood disorders (Cipriani mood disorders (Cipriani et al, et al, 2005; 2005; Baldessarini Baldessarini et al, et al, 2006 A subgroup analysis showed that the reducsubgroup analysis showed that the reduction in suicidal acts occurred in studies that tion in suicidal acts occurred in studies that included only patients with bipolar disorder included only patients with bipolar disorder as well as studies including a mix of paas well as studies including a mix of patients with major affective or schizoaffectients with major affective or schizoaffective disorders. In addition to decreasing tive disorders. In addition to decreasing the rate of suicidal acts, lithium appears the rate of suicidal acts, lithium appears to reduce the 'lethality of suicide', as indito reduce the 'lethality of suicide', as indicated by the ratio of attempted to comcated by the ratio of attempted to completed suicide. This ratio is usually much pleted suicide. This ratio is usually much lower for people with bipolar disorder lower for people with bipolar disorder (5:1) than the general population (20-(5:1) than the general population (20-30:1), and lithium treatment increases it 30:1), and lithium treatment increases it by about 2.9 times. The efficacy of lithium by about 2.9 times. The efficacy of lithium in reducing suicidal behaviour in spite of its in reducing suicidal behaviour in spite of its limited prophylactic effect for bipolar limited prophylactic effect for bipolar depression suggests that its anti-suicidal depression suggests that its anti-suicidal action might operate via domains other action might operate via domains other than depressed mood, possibly by an effect than depressed mood, possibly by an effect on impulsivity and aggression (inward or on impulsivity and aggression (inward or outward), both common in bipolar disorder outward), both common in bipolar disorder and both potential influences of suicidal and both potential influences of suicidal behaviour (Baldessarini behaviour (Baldessarini et al et al, 2006) . , 2006).
TREATMENT ADHERENCE TREATMENT ADHERENCE
Patients' adherence to lithium treatment is Patients' adherence to lithium treatment is of utmost importance because discontinuaof utmost importance because discontinuation increases the risk of manic relapse tion increases the risk of manic relapse (Goodwin, 1994 (2003, 2005) (2003, 2005 ) evaluated the effect of a 21-session strucevaluated the effect of a 21-session structured group psychoeducation programme tured group psychoeducation programme on patient outcome and serum lithium leon patient outcome and serum lithium levels in euthymic patients with bipolar disvels in euthymic patients with bipolar disorder over a 2-year period. Serum lithium order over a 2-year period. Serum lithium levels in the 49 patients who received levels in the 49 patients who received psychoeducation were significantly higher psychoeducation were significantly higher and more stable than in the 44 patients and more stable than in the 44 patients assigned to the control group (Colom assigned to the control group (Colom et et
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( 2 0 0 7 ) , 1 9 1 , 4 7 4^4 7 6 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 7. 0 4 3 13 3 ( 2 0 0 7 ) , 1 9 1 , 4 7 4^4 7 6 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 7. 0 4 3 13 3 (Young & Macritchie, 2004) . In tubular dysfunction, which is 2004). In tubular dysfunction, which is more common, the kidney's ability to more common, the kidney's ability to concentrate urine is reduced (Young & concentrate urine is reduced (Young & Macritchie, 2004) . Diabetes insipidus is Macritchie, 2004). Diabetes insipidus is marked by polyuria and polydypsia, and marked by polyuria and polydypsia, and can progress to severe dehydration; furthercan progress to severe dehydration; furthermore, the intraluminal lithium concenmore, the intraluminal lithium concentration can increase to toxic levels. tration can increase to toxic levels. Monitoring for diabetes insipidus, the most Monitoring for diabetes insipidus, the most common renal complication of lithium common renal complication of lithium therapy, is vital because it is initially therapy, is vital because it is initially reversible on lithium withdrawal but may reversible on lithium withdrawal but may become irreversible as a result of structural become irreversible as a result of structural damage. Annual assessment of urine prodamage. Annual assessment of urine production, which should not exceed 4 l in duction, which should not exceed 4 l in 24 h, is mandatory. In addition, patients 24 h, is mandatory. In addition, patients should be advised to see their doctor if they should be advised to see their doctor if they find they become excessively thirsty. find they become excessively thirsty. Although it is not possible to guarantee preAlthough it is not possible to guarantee prevention of lithium-induced diabetes insipivention of lithium-induced diabetes insipidus, the risk is reduced by employing the dus, the risk is reduced by employing the lowest therapeutic dose of lithium. In some lowest therapeutic dose of lithium. In some instances, lithium-induced diabetes insipiinstances, lithium-induced diabetes insipidus can be managed entirely by dose reducdus can be managed entirely by dose reduction, although combination therapy or tion, although combination therapy or lithium substitution is necessary in others. lithium substitution is necessary in others. Severe acute diabetes insipidus must be Severe acute diabetes insipidus must be treated by a renal specialist because restoratreated by a renal specialist because restoration of water and electrolyte levels is urgent tion of water and electrolyte levels is urgent in order to prevent lithium toxicity, neuroin order to prevent lithium toxicity, neurological impairment and encephalopathy. logical impairment and encephalopathy.
More rarely, lithium affects glomerular More rarely, lithium affects glomerular function, causing the glomerular filtration function, causing the glomerular filtration rate to decline, which can compromise rate to decline, which can compromise waste elimination and fluid-electrolyte waste elimination and fluid-electrolyte homoeostasis. Although glomerular dyshomoeostasis. Although glomerular dysfunction appears to be uncommon, it is function appears to be uncommon, it is advisable to conduct a baseline assessment advisable to conduct a baseline assessment of renal function before initiating lithium of renal function before initiating lithium treatment, including measurement of serum treatment, including measurement of serum electrolytes and creatinine, urinanalysis and electrolytes and creatinine, urinanalysis and blood urea nitrogen. Chronic renal failure blood urea nitrogen. Chronic renal failure may be asymptomatic in the early stages, may be asymptomatic in the early stages, so it is vital to monitor serum creatinine so it is vital to monitor serum creatinine at least every 6 months. Serum creatinine at least every 6 months. Serum creatinine is a crude measure of glomerular filtration is a crude measure of glomerular filtration rate and increasing creatinine levels and/or rate and increasing creatinine levels and/or levels greater than 140 levels greater than 140 m mmol/l signal a need mol/l signal a need for further assessment. for further assessment.
IS LITHIUM IS LITHIUM NEUROPROTECTIVE NEUROPROTECTIVE OR NEUROTOXIC ? OR NEUROTOXIC ?
There has been some debate as to whether There has been some debate as to whether long-term lithium therapy is neuroproteclong-term lithium therapy is neuroprotective or neurotoxic. (Struve, 1987) , slowing of motor and sensory nerve conduction (Chang and sensory nerve conduction (Chang et et al, al, 1990) and impairment of cerebellar con-1990) and impairment of cerebellar control of fast single-joint movement (Setta trol of fast single-joint movement (Setta et et al, al, 1998) . There is contradictory evidence 1998). There is contradictory evidence as to whether lithium therapy increases as to whether lithium therapy increases (Dunn (Dunn et al 
conducted a literature review and concluded that the literature review and concluded that the data concerning the neuroprotective/neurodata concerning the neuroprotective/neurotoxic effect of lithium therapy is 'unclear or toxic effect of lithium therapy is 'unclear or conflicting', since there is conflicting eviconflicting', since there is conflicting evidence from uncontrolled non-randomised dence from uncontrolled non-randomised studies and from animal and basic scientific studies and from animal and basic scientific studies. They therefore recommend mainstudies. They therefore recommend maintaining the clinical guidance to use lithium taining the clinical guidance to use lithium at the lowest therapeutic levels. at the lowest therapeutic levels.
CONCLUSIONS CONCLUSIONS
In recent years the number of pharmacoIn recent years the number of pharmacological agents available for treating patients logical agents available for treating patients with bipolar disorder has increased signifiwith bipolar disorder has increased significantly and some patients may be best cantly and some patients may be best treated by agents other than lithium. Howtreated by agents other than lithium. However, lithium continues to be the most effecever, lithium continues to be the most effective and best-tolerated treatment option for tive and best-tolerated treatment option for many patients. Psychiatrists should conmany patients. Psychiatrists should continue to include this efficacious treatment tinue to include this efficacious treatment in their arsenal for bipolar disorder. in their arsenal for bipolar disorder. 
